Markers of left ventricular decompensation in aortic stenosis

Expert Review of Cardiovascular Therapy

Volumn 12, Issue 7, 2014, Pages 901-912

  Chin, Calvin W L ^a,b   Vassiliou, Vassilis ^c   Jenkins, William S A ^a   Prasad, Sanjay K ^c   Newby, David E ^a   Dweck, Marc R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

aortic stenosis; cardiac MRI; echocardiography; left ventricular decompensation; left ventricular hypertrophy; myocardial fibrosis; myocardial T1 mapping; myocyte death; tissue Doppler imaging

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARDIAC TROPONIN; TROPONIN; UNCLASSIFIED DRUG;

AORTA STENOSIS; AORTA VALVE REPLACEMENT; DIASTOLIC DYSFUNCTION; DISEASE MARKER; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE FIBROSIS; HUMAN; LEFT VENTRICULAR DECOMPENSATION; PATHOPHYSIOLOGY; REVIEW; STRESS; AORTA VALVE STENOSIS; COMPLICATION; SEVERITY OF ILLNESS INDEX;

AORTIC VALVE STENOSIS; BIOMARKERS; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; SEVERITY OF ILLNESS INDEX;

EID: 84903118981     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2014.923307     Document Type: Review

References (118)

1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368(9540):1005-11
2. Carabello BA. Introduction to aortic stenosis. Circ Res 2013;113(2):179-85
3. Rajamannan NM, Evans FJ, Grande-Allen KJ, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute aortic stenosis working group executive summary: calcific aortic valve disease-2011 update. Circulation 2011;124:1783-91
4. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol 2012;60: 1854-63
5. Dweck MR, Jones C, Joshi NV, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosisclinical perspective. Circulation 2012;125(1):76-86
6. Ross J, Braunwald E. Aortic stenosis. Circulation 1968;38:61-7
7. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012;33(19): 2451-96
8. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118(15):e523-661
9. Greve AM, Boman K, Gohlke-Baerwolf C, et al. Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the simvastatin and ezetimibe in aortic stenosis study. Circulation 2012;125(2):346-53
10. Pellikka PA. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 2005;111(24):3290-5
11. Brown ML, Pellikka PA, Schaff HV, et al. The benefits of early valve replacement in asymptomatic patients with severe aortic stenosis. J Thorac Cardiovasc Surg 2008; 135(2):308-15
12. Kang D-H, Park S-J, Rim JH, et al. Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation 2010;121(13):1502-9
13. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000;102(4):470-9
14. Gunther S, Grossman W. Determinants of ventricular function in pressure-overload hypertrophy in man. Circulation 1979; 59(4):679-88
15. Dweck MR, Joshi S, Murigu T, et al. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:50
16. Salcedo EE, Korzick DH, Currie PJ, et al. Determinants of left ventricular hypertrophy in patients with aortic stenosis. Cleve Clin J Med 1989;56(6):590-6
17. Kupari M, Turto H, Lommi J. Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? Eur Heart J 2005;26(17):1790-6
18. Seiler C, Jenni R. Severe aortic stenosis without left ventricular hypertrophy: prevalence, predictors, and short-term follow up after aortic valve replacement. Heart 1996;76(3):250-5
19. Carroll JD, Carroll EP, Feldman T, et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992;86(4):1099-107
20. Montalvo C, Villar AV, Merino D, et al. Androgens contribute to sex differences in myocardial remodeling under pressure overload by a mechanism involving TGF-b. PLoS One 2012;7(4):e35635
21. Douglas PS, Otto CM, Mickel MC, et al. Gender differences in left ventricle geometry and function in patients undergoing balloon dilatation of the aortic valve for isolated aortic stenosis. NHLBI balloon valvuloplasty registry. Br Heart J 1995;73(6):548-54
22. Villari B, Campbell SE, Schneider J, et al. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. Eur Heart J 1995;16(10):1410-19
23. Regitz-Zagrosek V, Oertelt-Prigione S, Seeland U, et al. Sex and gender differences in myocardial hypertrophy and heart failure. Circ J 2010;74(7):1265-73
24. Orlowska-Baranowska E, Placha G, Gaciong Z, et al. Influence of ACE I/D genotypes on left ventricular hypertrophy in aortic stenosis: gender-related differences. J Heart Valve Dis 2004;13(4):574-81
25. Antonini-Canterin F, Huang G, Cervesato E, et al. Symptomatic aortic stenosis: does systemic hypertension play an additional role? Hypertension 2003;41(6): 1268-72
26. Rieck AE, Cramariuc D, Staal EM, et al. Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy). J Hypertens 2010;28(2):377-83
27. Pagé A, Dumesnil JG, Clavel M-A, et al. Metabolic syndrome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin). J Am Coll Cardiol 2010; 55(17):1867-74
28. Lund BP, Gohlke-Bärwolf C, Cramariuc D, et al. Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic Stenosis [SEAS] substudy). Am J Cardiol 2010;105(10): 1456-60
29. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the Valvuloarterial Impedance to Predict Adverse Outcome in Asymptomatic Aortic Stenosis. J Am Coll Cardiol 2009;54(11):1003-11
30. Lancellotti P, Donal E, Magne J, et al. Risk stratification in asymptomatic moderate to severe aortic stenosis: the importance of the valvular, arterial and ventricular interplay. Heart 2010;96(17):1364-71
31. Garcia D. A ventricular-vascular coupling model in presence of aortic stenosis. Am J Physiol Heart Circ Physiol 2004;288(4): H1874-84
32. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18(12). 1440-63
33. Pibarot P, Dumesnil JG. Low-flow, low-gradient aortic stenosis with normal and depressed left ventricular ejection fraction. J Am Coll Cardiol 2012;60(19):1845-53
34. Huber D, Grimm J, Koch R, et al. Determinants of ejection performance in aortic stenosis. Circulation 1981;64(1): 126-34
35. Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart structural deterioration and compensatory mechanisms. Circulation 2003;107(7):984-91
36. González A, López B, Ravassa S, et al. Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension 2002;39(1):75-80
37. Tokuda K, Kai H, Kuwahara F, et al. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 2004;43(2):499-503
38. Communal C, Singh K, Pimentel DR, et al. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998;98(13):1329-34
39. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83(6):1849-65
40. Marcus ML, Koyanagi S, Harrison DG, et al. Abnormalities in the coronary circulation that occur as a consequence of cardiac hypertrophy. Am J Med 1983; 75(3A):62-6
41. Galiuto L, Lotrionte M, Crea F, et al. Impaired coronary and myocardial flow in severe aortic stenosis is associated with increased apoptosis: a transthoracic Doppler and myocardial contrast echocardiography study. Heart 2006;92(2):208-12
42. Schaper J, Speiser B. The extracellular matrix in the failing human heart. Basic Res Cardiol 1992;87(Suppl 1):303-9
43. Mewton N, Liu CY, Croisille P, et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 2011;57(8):891-903
44. Bing OH, Ngo HQ, Humphries DE, et al. Localization of alpha1(I) collagen mRNA in myocardium from the spontaneously hypertensive rat during the transition from compensated hypertrophy to failure. J Mol Cell Cardiol 1997;29(9):2335-44
45. Villari B, Campbell SE, Hess OM, et al. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J am Coll Cardiol 1993;22(5):1477-84
46. Weidemann F, Herrmann S, Störk S, et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009;120(7):577-84
47. Murphy ML, Thenabadu PN, de Soyza N, et al. Sensitivity of electrocardiographic criteria for left ventricular hypertrophy according to type of cardiac disease. Am J Cardiol 1985;55(5):545-9
48. Dahl JS, Christensen NL, Videbaek L, et al. Left ventricular diastolic function is associated with symptom status in severe aortic valve stenosis. Circ Cardiovasc Imaging 2014;7(1):142-8
49. Cioffi G, Faggiano P, Vizzardi E, et al. Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Heart 2011;97(4):301-7
50. Greve AM, Gerdts E, Boman K, et al. Differences in cardiovascular risk profile between electrocardiographic hypertrophy versus strain in asymptomatic patients with aortic stenosis (from SEAS Data). Am J Cardiol 2011;108(4):541-7
51. Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension 2002;39(3):750-5
52. Grothues F, Smith GC, Moon JCC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002;90(1):29-34
53. Dweck MR, Joshi S, Murigu T, et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J am Coll Cardiol 2011;58(12):1271-9
54. Smith N, McAnulty JH, Rahimtoola SH. Severe aortic stenosis with impaired left ventricular function and clinical heart failure: results of valve replacement. Circulation 1978;58(2):255-64
55. Connolly HM, Oh JK, Orszulak TA, et al. Aortic valve replacement for aortic stenosis with severe left ventricular dysfunction. Prognostic indicators. Circulation 1997; 95(10):2395-400
56. Dumesnil JG, Shoucri RM. Effect of the geometry of the left ventricle on the calculation of ejection fraction. Circulation 1982;65(1):91-8
57. Pibarot P, Dumesnil JG. Improving assessment of aortic stenosis. JAm Coll Cardiol 2012;60(3):169-80
58. Lancellotti PP, Donal EE, Magne JJ, et al. Impact of global left ventricular afterload on left ventricular function in asymptomatic severe aortic stenosis: a two-dimensional speckle-tracking study. Eur J Echocardiogr 2010;11(6):537-43
59. Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. JAm Coll Cardiol 1995;26(1):195-202
60. Ballo P, Mondillo S, Motto A, Faraguti SA. Left ventricular midwall mechanics in subjects with aortic stenosis and normal systolic chamber function. J Heart Valve Dis 2006;15(5):639-50
61. Cramariuc D, Cioffi G, Rieck E, et al. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. JACC Cardiovasc Imaging 2009;2(4):390-9
62. Lam CSP, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted county, Minnesota. Circulation 2007; 115(15):1982-90
63. Takeda S, Rimington H, Smeeton N, et al. Long axis excursion in aortic stenosis. Heart 2001;86(1):52-6
64. Manovel A, Dawson D, Smith B, et al. Assessment of left ventricular function by different speckle-tracking software. Eur J Echocardiogr 2010;11(5):417-21
65. Blessberger H, Binder T. Two dimensional speckle tracking echocardiography: basic principles. Heart 2010;96(9):716-22
66. Cramariuc D, Gerdts E, Davidsen ES, et al. Myocardial deformation in aortic valve stenosis: relation to left ventricular geometry. Heart 2010;96(2):106-12
67. Ng ACT, Delgado V, Bertini M, et al. Alterations in multidirectional myocardial functions in patients with aortic stenosis and preserved ejection fraction: a two-dimensional speckle tracking analysis. Eur Heart J 2011;32(12):1542-50
68. Delgado V, Tops LF, van Bommel RJ, et al. Strain analysis in patients with severe aortic stenosis and preserved left ventricular ejection fraction undergoing surgical valve replacement. Eur Heart J 2009;30(24): 3037-47
69. Lancellotti P, Donal E, Magne J, et al. Risk stratification in asymptomatic moderate to severe aortic stenosis: the importance of the valvular, arterial and ventricular interplay. Heart 2010;96(17):1364-71
70. Hess OM, Villari B, Krayenbuehl HP. Diastolic dysfunction in aortic stenosis. Circulation 1993;87(5 Suppl):IV73-6
71. Bruch C, Stypmann J, Grude M, et al. Tissue Doppler imaging in patients with moderate to severe aortic valve stenosis: clinical usefulness and diagnostic accuracy. Am Heart J 2004;148(4):696-702
72. Villari B, Hess OM, Kaufmann P, et al. Effect of aortic valve stenosis (pressure overload) and regurgitation (volume overload) on left ventricular systolic and diastolic function. Am J Cardiol 1992; 69(9):927-34
73. Biner S, Rafique AM, Goykhman P, et al. Prognostic value of E/É ratio in patients with unoperated severe aortic stenosis. JACC Cardiovasc Imaging 2010;3(9): 899-907
74. Stewart RAH, Kerr AJ, Whalley GA, et al. Left ventricular systolic and diastolic function assessed by tissue Doppler imaging and outcome in asymptomatic aortic stenosis. Eur Heart J 2010;31(18):2216-22
75. Park SJ, Enriquez-Sarano M, Chang SA, et al. 1-s2.0-S1936878X12009539- main. JACC Cardiovasc Imaging 2013;6(2): 137-46
76. Casaclang-Verzosa G, Malouf JF, Scott CG, et al. Does left atrial size predict mortality in asymptomatic patients with severe aortic stenosis? Echocardiography 2010;27(2): 105-9
77. Greve AM, Gerdts E, Boman K, et al. Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the simvastatin and ezetimibe in aortic stenosis study. Int J Cardiol 2013;166(1):72-6
78. Rafique AM, Biner S, Ray I, et al. Meta-analysis of prognostic value of stress testing in patients with asymptomatic severe aortic stenosis. Am J Cardiol 2009;104(7): 972-7
79. Amato MC, Moffa PJ, Werner KE, et al. Treatment decision in asymptomatic aortic valve stenosis: role of exercise testing. Heart 2001;86(4):381-6
80. Gerber IL, Stewart RAH, Legget ME, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003;107(14):1884-90
81. Nessmith MG, Fukuta H, Brucks S, et al. Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol 2005;96(10):1445-8
82. Ben-Dor I, Minha S, Barbash IM, et al. Correlation of brain natriuretic peptide levels in patients with severe aortic stenosis undergoing operative valve replacement or percutaneous transcatheter intervention with clinical, echocardiographic, and hemodynamic factors and prognosis. Am J Cardiol 2013;112(4):574-91
83. Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004;109(19): 2302-8
84. Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol 2004;94(6):740-5
85. Monin J-L, Lancellotti P, Monchi M, et al. Risk score for predicting outcome in patients with asymptomatic aortic stenosis. Circulation 2009;120(1):69-75
86. Lancellotti P, Moonen M, Magne J, et al. Prognostic effect of long-axis left ventricular dysfunction and B-type natriuretic peptide levels in asymptomatic aortic stenosis. Am J Cardiol 2010;105(3):383-8
87. Cimadevilla C, Cueff C, Hekimian G, et al. Prognostic value of B-type natriuretic peptide in elderly patients with aortic valve stenosis: the COFRASA-GENERAC study. Heart 2013;99(7):461-7
88. Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89(7):745-51
89. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47(2):345-53
90. Ikeda T, Matsuda K, Itoh H, et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 1997;133(3): 307-14
91. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Nat Rev Cardiol 2012;9(11): 620-33
92. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58(11):1574-81
93. Røsjø H, Andreassen J, Edvardsen T, et al. Prognostic usefulness of circulating high-sensitivity troponin T in aortic stenosis and relation to echocardiographic indexes of cardiac function and anatomy. Am J Cardiol 2011;108(1):88-91
94. Chin CWL, Shah AS, McAllistair D, et al. High sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J 2014 doi:10.1093/ eurheartj/ehu189 [Epub ahead of print]
95. Villari B, Vassalli G, Monrad ES, et al. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 1995;91(9):2353-8
96. McCrohon JA, Moon JCC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003;108(1):54-9
97. Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005;26(15):1461-74
98. Weidemann F, Niemann M, Herrmann S, et al. A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. Eur Heart J 2007;28(24):3020-6
99. Quarto C, Dweck MR, Murigu T, et al. Late gadolinium enhancement as a potential marker of increased perioperative risk in aortic valve replacement. Interact Cardiovasc Thorac Surg 2012;15(1):45-50
100. Azevedo CF, Nigri M, Higuchi ML, et al. Prognostic Significance of Myocardial Fibrosis Quantification by Histopathology and Magnetic Resonance Imaging in Patients With Severe Aortic Valve Disease. J Am Coll Cardiol 2010;56(4):278-87
101. Milano AD, Faggian G, Dodonov M, et al. Prognostic value of myocardial fibrosis in patients with severe aortic valve stenosis. J Thorac Cardiovasc Surg 2012;144(4): 830-7
102. D́iez J, Querejeta R, López B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002;105(21):2512-17
103. López B, González A, Beaumont J, et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007;50(9):859-67
104. López B, Querejeta R, González A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Cardiol 2004; 43(11):2028-35
105. Chin C, Semple S, Malley T, et al. Optimization and comparison of myocardial T1 mapping techniques at 3T in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging 2014;15(5):556-65
106. Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 2012;126(10): 1206-16
107. Schindler TH, Lima JAC. Editorial-Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 2014;35(10): 657-64
108. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110(19): 3121-8
109. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010;7(1):1-8
110. Liu YH, D'Ambrosio M, Liao TD, et al. N-acetyl-seryl-aspartyl-lysyl- proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009;296(2):H404-12
111. van Kimmenade RR, Januzzi JL, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Cardiol 2006;48(6):1217-24
112. de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2011;272(1): 55-64
113. Lok DJ, Lok SI, Bruggink-André de la Porte PW, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 2012;102(2):103-10
114. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010;12(8):826-32
115. Jenkins W, Chin C, Rudd J, et al. What can we learn about valvular heart disease from PET/CT? Future Cardiology 2013; 9(5):657-67
116. Lygoe KA, Norman JT, Marshall JF, et al. AlphaV integrins play an important role in myofibroblast differentiation. Wound Repair Regen 2004;12(4):461-70
117. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res 2006;312(5):651-8
118. Schwarz F, Baumann P, Manthey J, et al. The effect of aortic valve replacement on survival. Circulation 1982;66(5):1105-10